

presence or absence of calcium, although the ATPase rates are very different. They suggest that in the absence of calcium a kinetic step, perhaps release of phosphate, is inhibited. This would also be quite consistent with our model.

Received 12 May; accepted 16 July 1982.

1. Taylor, K. A. & Amos, L. A. *J. molec. Biol.* **147**, 297–324 (1981).
2. Moore, P. B., Huxley, H. E. & DeRosier, D. J. *J. molec. Biol.* **50**, 279–295 (1970).
3. Holmes, K. C., Goody, R. S. & Amos, L. A. *Ultramicroscopy* (in the press).
4. Mornet, D., Bertrand, R., Pantel, P., Audemard, E. & Kassab, R. *Nature* **292**, 301–306 (1981).
5. Wakabayashi, T. & Toyoshima, C. *J. Biochem., Tokyo* **90**, 683–701 (1981).
6. Vibert, P. & Craig, R. *J. molec. Biol.* **157**, 299–319 (1982).
7. Mendelson, R. *Nature* **298**, 665–667 (1982).
8. Huxley, A. F. & Simmons, R. M. *Nature* **233**, 533–583 (1971).
9. Huxley, H. E. *et al. Proc. natn. Acad. Sci. U.S.A.* **78**, 2297–2301 (1981).
10. Harrison, S. C., Olson, A. J., Schutt, C. E., Winkler, F. K. & Bricogne, G. *Nature* **276**, 368–373 (1978).
11. Cooke, R. *Nature* **294**, 570–571 (1981).
12. Spudich, J. A., Huxley, H. E., Finch, J. T. *J. molec. Biol.* **72**, 619–632 (1972).
13. Wakabayashi, T., Huxley, H. E., Amos, L. A. & Klug, A. *J. molec. Biol.* **93**, 477–497 (1975).
14. Seymour, J. & O'Brien, E. *Nature* **283**, 680–682 (1980).
15. Chalovich, J. M. & Eisenberg, E. *J. biol. Chem.* **257**, 2432–2437 (1982).
16. DeRosier, D. J. & Klug, A. *Nature* **217**, 130–134 (1968).
17. Greene, L. E. & Eisenberg, E. *Proc. natn. Acad. Sci. U.S.A.* **77**, 2616–2620 (1980).
18. Suck, D., Kabsch, W. & Mannherz, H. G. *Proc. natn. Acad. Sci. U.S.A.* **78**, 4319–4323 (1981).

Structure of a Zn^{2+} -containing D-alanyl-D-alanine-cleaving carboxypeptidase at 2.5 Å resolution

O. Dideberg*, P. Charlier†, G. Dive‡, B. Joris†, J. M. Frère† & J. M. Ghuyse†

* Laboratoire de Cristallographie, Institut de Physique, B5, Université de Liège, B-4000 Sart Tilman, Liège, Belgium

† Service de Microbiologie appliquée aux Sciences pharmaceutiques, Institut de Chimie, B6, Université de Liège, B-4000 Sart Tilman, Liège, Belgium

‡ Laboratoire de Chimie analytique, Institut de Pharmacie, F1, Université de Liège, Rue Fusch 3–5, B-4000 Liège, Belgium

Bacteria possess proteases that are specific for the peptide bonds between D-alanine residues, one of which has a free α -carboxyl group. These D-alanyl-D-alanine peptidases catalyse carboxypeptidation and transpeptidation reactions involved in bacterial cell wall metabolism^{1,2}, and are inactivated by β -lactam antibiotics. We have now elucidated the structure, at 2.5 Å resolution, of the penicillin-resistant Zn^{2+} -containing D-alanyl-D-alanine peptidase of *Streptomyces albus* (Zn^{2+} G peptidase)^{3,4}. The enzyme is shown to consist of two globular domains, connected by a single link. The N-terminal domain has three α -helices, and the C-terminal domain has three α -helices and five β -strands. The Zn^{2+} ion is ligated by three histidine residues, and located in a cleft in the C-terminal domain. The mechanism of action of the enzyme may be related to that of other carboxypeptidases, which also contain functional Zn^{2+} ions.

Crystals of the Zn^{2+} G peptidase were grown⁵, using the vapour diffusion technique, from a solution containing 50 mM Tris-HCl pH 8.0, 5 mM $MgCl_2$, 10 mM NaN_3 and a protein concentration of 2%. The crystals were prismatic and belonged to the space group $P2_1$ ($a = 51.1$ Å, $b = 49.7$ Å, $c = 38.7$ Å and $\beta = 100.6^\circ$). The asymmetric unit contained one protein molecule. The heavy-atom derivatives were prepared by soaking native crystals in appropriate solutions: 5.6 mM $K_2Pt(C_2O_4)_2$, 3 mM $NaAuCl_4$ and 30 mM $K_3UO_2F_5$. X-ray diffraction data were collected on a four-circle diffractometer (Hilger-Watts) with a Ni-filtered $CuK\alpha$ radiation and an ω -scan procedure. Two equivalent reflections for the native and four for the derivatives, including Bijvoet pairs, were measured in shells of increasing θ values. The heavy-atom sites were located using F_{HLE} Patterson functions⁶. Heavy-atom parameters were refined by the F_{HLE} procedure, followed by three cycles of phase refinement. The mean figure of merit was 0.66 for 6,700 reflections. Despite this rather low value, the high quality of the electron density map can be judged from Fig. 1.

The interpretation of the 2.5 Å electron density map of the Zn^{2+} G peptidase was carried out more or less simultaneously




Fig. 1 The electron density map in two different regions of the molecule. *a*, Two large side chains at the end of the cleft: Tyr 154 and His 156. *b*, A well defined S–S bridge: Cys 168–Cys 210.




Fig. 2 Schematic drawing of the model of the Zn^{2+} G enzyme built from secondary structure elements. α -Helices and β -strands are represented by cylinders and arrows, respectively. The N and C terminus of the polypeptide chain and the S–S bridges are shown.

with the establishment of its primary structure. Initially, the N-terminal 55 residues and the C-terminal 45 residues could be located directly on the mini-map and six fragments (totalling 84 residues) could be correctly positioned using the Evans-Sutherland graphic system (at the University of London). However, examination of all possible tracings of the polypeptide chain and re-evaluation of the C^α – C^α distances led to the conclusion that a 28-residue fragment was missing. This fragment was subsequently isolated and sequenced so that, at this time, the two techniques are in agreement except for a few residues located outside the catalytic cavity. The complete sequence will be published elsewhere⁷, but Table 1 gives the




Fig. 3 Stereoscopic views of the main polypeptide chain. The α -carbon positions were derived from the mini-map. Important amino acid residues are labelled using the one-letter code.

positions and proposed functions of some critical amino acid residues.

Besides the Zn^{2+} ion, cystines 92–140 and 168–210 were the most prominent features of the electron density map. Electron density at the methionine residues was rather weak and the weakest Met 153 was located near an Au-binding site. Tracing the polypeptide chain was easy except for two regions, $C^{\alpha 76}$ – $C^{\alpha 82}$ and $C^{\alpha 90}$ – $C^{\alpha 95}$, respectively. The enzyme molecule has an overall dimension of $48 \text{ \AA} \times 34 \text{ \AA} \times 28 \text{ \AA}$ and consists of two distinct globular domains of different sizes (Figs 2, 3). The small N-terminal domain (76 residues) contains three α -helices (43%) and is connected to the large C-terminal domain (136 residues) by a single link that exhibits a rather unusual folding. The C-terminal domain belongs to the α/β -type secondary structure⁸, containing three α -helices (34%) and five β -strands (17%). About 38% and 11% of the total number of amino acid residues are comprised of α -helix (80 residues) and β -structure (23 residues), respectively. To our knowledge, such a secondary structure has not been found previously in any other protein.

The five β -strands of the C-terminal domain form a mixed sheet with the usual left-handed twist. The cross-over connection is right-handed, a widely observed rule in protein folding⁹. This sheet constitutes the lining of one side of the catalytic cavity. Other remarkable features of the C-terminal domain are the long, 24-residue-containing helix and, especially, the two loops ($C^{\alpha 186}$ – $C^{\alpha 193}$ and $C^{\alpha 138}$ – $C^{\alpha 152}$) which, in turn, form the edges of the catalytic cavity. This cavity cuts the C-terminal domain into two parts, with the Zn^{2+} cofactor bound inside coordinated with the three protein ligands His 152, His 193 and His 196. Previous studies at 4.5 \AA resolution¹⁰ have shown this cleft to be the binding site of the two enzyme competitive inhibitors, the dipeptide acetyl-D-Ala-D-Glu and the β -lactam compound *p*-iodo-7- β -phenylacetylaminoccephalosporanic acid. The cavity of the native enzyme was not free of electron density; this might be due either to the presence of ordered solvent molecules or to spurious peaks originating from the heavy-atom binding sites. (In fact, each of the three heavy-atom derivatives studied had at least one binding site inside the cavity.)

A full characterization of the catalytic cavity of the Zn^{2+} G peptidase must await the final fitting of the protein molecule in the Richard's box and crystallographic refinements. Similarly, a full identification of all the residues involved in the binding and catalytic processes must await study at high resolution of various inhibitor (inactivator)–enzyme complexes. Neverthe-

less, at the present stage of the analysis, one may make interesting hypotheses concerning the mechanistic properties of this peptidase. Most likely, Arg 136 is concerned with binding, by charge pairing, of the carboxylate substrate. In addition, two Asp residues (159 and 192) and His 190 are located near the Zn^{2+} cofactor and their side chains have the right orientation to interact with the bound peptide substrate molecule. Contrary to all the other β -lactam compounds tested, β -iodopenicillanate bound irreversibly to the catalytic cavity of the Zn^{2+} G peptidase in rather mild conditions (unpublished results). The difference Fourier synthesis at 2.8 \AA resolution of the complex thus formed showed two peaks in the vicinity of Arg 136 and His 190, respectively. Permanent inactivation of the peptidase may be due to alkylation of this His residue.

In the proposed catalytic mechanism of carboxypeptidase A and thermolysin^{11–14}, the Zn^{2+} ion functions as a negative-charge stabilizer, the side-chain oxygen of a Glu residue as a proton abstractor (with or without a water molecule as the nucleophile), and a His or Tyr residue as a proton donor. By analogy, one may propose that in the Zn^{2+} G peptidase, Asp 159 or Asp 192 also acts as proton abstractor and His 190 as proton donor. Following this view, the Zn^{2+} G peptidase would be mechanistically similar to the usual metallopeptidases and its specificity would depend entirely on the shape and structural features of its substrate binding cavity.

Two further comments deserve attention. Contrary to observations on carboxypeptidase A, whose active centre is a closed cavity, that of the Zn^{2+} G peptidase is an open cleft. This feature, which is reminiscent of that of thermolysin, should permit accommodation of extended structures. It might be related to the ability of the Zn^{2+} G peptidase to perform endopeptidase activities effectively on complex peptide substrates (possessing a free carbonyl group in α position to the scissile linkage)¹⁵. Finally, the role of the small N-terminal domain remains unknown.

This work was supported in part by the FRSM, Brussels (3.4501.79), the Belgian Government (Action concertée 79/84-11) and the NIH (2 RO1 13364-05). O.D. thanks EMBO, NATO and the FNRS (contracts 52/5-F6-E20 and 52/5-CG-E47) for financial support. We thank Professor T. L. Blundell for making available his interactive display system, and Professor J. Toussaint, Dr I. Tickle, Dr G. Wistow, Dr J. Lamotte-Brasseur and Mr M. Vermeire for help during this work.

Received 14 April; accepted 23 June 1982.

Table 1 Positions and proposed functions of some critical amino acid residues

Asn–Gly 1–2	N-terminal*
Cystine 3–80	S–S bridge
Cystine 92–140	S–S bridge
Cystine 168–210	S–S bridge
His 152, His 193, His 196	Zn^{2+} ligands
Arg 136	Charge pairing with substrate
Asp 159 or 192	Proton abstractor
His 190	Proton donor
Ile 212	C-terminal

* Partly in the form of a cyclic imide.

- Ghuysen, J. M. *et al.* in *Topics in Molecular Pharmacology* (eds Burgen, A. S. V. & Roberts, G. C. K.) 63–97 (Elsevier, Amsterdam, 1981).
- Waxman, D. J., Yocum, R. R. & Strominger, J. L. *Phil. Trans. R. Soc. B* **289**, 257–271 (1980).
- Frère, J. M. *et al.* *Biochem. J.* **143**, 233–240 (1974).
- Dideberg, O. *et al.* *FEBS Lett.* **117**, 215–218 (1980).
- Dideberg, O., Frère, J. M. & Ghuysen, J. M. *J. molec. Biol.* **129**, 677–679 (1979).
- Matthews, B. W. *Acta crystallogr.* **20**, 82–86 (1966).
- Joris, B. *et al.* *Eur. J. Biochem.* (submitted).
- Levitt, H. & Chothia, C. *Nature* **261**, 552–557 (1976).
- Richardson, J. *Proc. natn. Acad. Sci. U.S.A.* **73**, 2619–2623 (1976).
- Dideberg, O. *et al.* *FEBS Lett.* **117**, 212–214 (1980).
- Hartsuck, J. A. & Lipscomb, W. N. in *The Enzymes* Vol. 3, 3rd edn (ed. Boyer, P. D.) 1–56 (Academic, New York, 1971).
- Kester, W. R. & Matthews, B. W. *J. biol. Chem.* **252**, 7704–7710 (1977).
- Argos, P., Garavito, R. M., Eventoff, W., Rossmann, M. & Bränden, C. I. *J. molec. Biol.* **126**, 141–158 (1978).
- Kuo, L. C. & Makinen, M. W. *J. biol. Chem.* **257**, 24–27 (1982).
- Leyh-Bouille, M. *et al.* *Biochemistry* **9**, 2961–2971 (1970).